Guangzhou Innogen Pharmaceutical Group Co Ltd
Company Profile
Business description
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize an innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize innovative therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates targeting diabetes and other metabolic diseases.
Contact
No. 2 Tengfei Second Street
Room 409, Building H Self-numbered Creative Building
China-Singapore Guangzhou Knowledge City
Huangpu District, Guangdong Province
Guangzhou
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
96
Stocks News & Analysis
stocks
3 ASX opportunities after earnings season
stocks
Oracle earnings: Solid execution secures revenue target and mitigates investor concerns
stocks
US dividend shares are getting a boost from the HALO trade. Can it last?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,793.40 | 1.40 | -0.02% |
| CAC 40 | 7,884.46 | 27.07 | -0.34% |
| DAX 40 | 23,408.10 | 39.19 | -0.17% |
| Dow JONES (US) | 46,558.47 | 119.38 | -0.26% |
| FTSE 100 | 10,268.20 | 7.05 | 0.07% |
| HKSE | 25,834.02 | 368.42 | 1.45% |
| NASDAQ | 22,105.36 | 206.62 | -0.93% |
| Nikkei 225 | 53,751.15 | 68.46 | -0.13% |
| NZX 50 Index | 13,164.58 | 22.76 | -0.17% |
| S&P 500 | 6,632.19 | 40.43 | -0.61% |
| S&P/ASX 200 | 8,583.40 | 7.80 | 0.09% |
| SSE Composite Index | 4,084.79 | 10.66 | -0.26% |